[Managing HIV infection. 2 new aspects].
PROTEASE SPARING REGIMEN: Due to the problems of tolerance an acceptability of tritherapy regimens, generally composed of 2 nucleosidic reverse transcription inhibitors (NRTI) and a protease inhibitor (PI), it might be beneficial to use a protease sparing regimen replacing the PI by a third antiretroviral agent. HIV/HCV CO-INFECTION: Co-infection with the hepatitis C virus may seriously compromise long-term survival due to the rapid progression of HCV infection to chronic hepatitis and/or cirrhosis.
Katlama
C
C
Service Pr. Bricaire, Groupe Hospitalier Pitié-Salpêtrière, Paris.
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006526:Hepatitis C / Q000188:drug therapy; D006801:Humans
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors